Developer docs
API playgroundTry for free, no card

Search company profiles

Kerecis

Full company profile

uuid00008uj

Namestring
Kerecis
Legal namestring
Kerecis
Websiteurl
kerecis.com
Company typeenum
Private
Founded yearint
2013
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersÍsafjörður, Iceland
HQ citystring
Ísafjörður
HQ countrystring
Iceland
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
fish skin grafts, wound care medical devices, tissue regeneration products, skin substitute grafts, burn care biologics
Industry3 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAMANAG
Wound Healing & Dermatologic Regeneration
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Wound Care Medical Devices
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeOne Time License
Description

Kerecis generates revenue through the sale of fish-skin based medical devices for wound care, burn treatment, and surgical applications. Products are sold through healthcare providers, hospitals, and authorized distributors. The company operates as a subsidiary of Coloplast following acquisition.

kerecis.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1CMS Reimbursement Rate - $127/cm²
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Standardized reimbursement rate of $127 per cm² set by CMS for skin substitute products effective January 2026. Kerecis average outpatient Medicare price approximately $110/cm².

kerecis.com
2MariGen Product Pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

MariGen products priced below the flat rate of $127.14 per cm² for hospital outpatient departments, ambulatory surgical centers, physician offices, and home health providers.

kerecis.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 15 records shown
1MariGen
Description

Fish-skin graft product line for chronic wound management including diabetic foot ulcers, venous leg ulcers, and other hard-to-heal wounds. Available in multiple variations: Solid (intact fish skin), Fenestrated (pre-fenestrated for exudate drainage), Micro (fragmented for deep wound spaces), and Expanse (2:1 pre-meshed for large wounds).

kerecis.com
+14 more records
Core offering1 text field

Kerecis develops and manufactures fish-skin based medical devices for wound healing, burn treatment, and surgical applications. The company uses intact fish skin from wild Atlantic cod sustainably sourced from Icelandic waters as a minimally processed, homologous-to-human-skin graft that supports true tissue regeneration. Its product portfolio includes the MariGen line for chronic wounds, Shield for wound care with silicone backing, SurgiClose and SurgiBind for surgical/operating room applications, and GraftGuide for burn management, supplemented by international product lines and a veterinary offering.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 8 values shown
  • 44% wound healing at 16 weeks vs 26.4% with standard of care for deep DFUs (Odinn RCT)
+7 more records
Product overview1 text field

Kerecis is a medical device company that has developed a proprietary fish-skin technology platform for tissue regeneration and wound healing. The company's products are based on intact fish skin sourced from wild Atlantic cod harvested from sustainable Icelandic fish stocks. The core portfolio includes MariGen (wound care - US), Shield (wound care with silicone backing), SurgiClose/SurgiClose Silicone (surgical applications), SurgiBind (operating room products), and GraftGuide (burn care). These products can be stacked or interspersed in deep wounds to fill deficits and support granulation tissue formation. The fish skin technology is homologous to human skin, provides structural support for cell ingrowth and vascularization, and maintains a natural bacterial barrier. Kerecis also offers veterinary products under the Kerecis VET brand and consumer products under the MariCell line for International/EU markets. The company provides digital services through Kerecis Current. All products are derived from sustainably sourced fish skin, processed using renewable energy with no harsh chemicals, and have a 3-year shelf life with room temperature storage.

Product and service16 records
1MariGen
CategoryWound Care Medical Devices
Description

Intact fish-skin graft product line for wound healing including diabetic foot ulcers, venous leg ulcers, and other chronic wounds. FDA-cleared with labeled intended use for full-thickness wounds with exposed bone and tendon. Available in Solid, Fenestrated, Micro, and Expanse variants.

2Shield
CategoryWound Care Medical Devices
Description

Fish-skin graft product with perforated silicone backing that protects the graft while managing exudate and wound moisture. Includes Shield Adhesive variant for outpatient wound care. Covered under CMS skin substitute program.

3SurgiClose
CategorySurgical Wound Care Devices
Description

Intact fish-skin graft designed for operating room usage, including surgical and trauma wound care applications. SurgiClose Silicone combines intact fish skin with a non-adhesive silicone layer for exudate and moisture management; available in multiple sizes from 3x3 cm to 10x10 cm (bordered and borderless). SurgiClose Micro is fragmented for deep wound spaces.

4SurgiBind
CategorySurgical Wound Care Devices
Description

Fish-skin graft product for operating room and surgical applications. SurgiBind Tendon Protect is designed to protect and manage newly repaired tendons to minimize scarring and adhesions. Available in fenestrated version for wound management.

5GraftGuide
CategoryBurn Care Medical Devices
Description

Intact fish-skin graft used for burn wound management to support tissue regeneration and healing. Clinical evidence shows shorter hospital stays for severely burned patients treated with fish-skin grafts compared to synthetic products.

6MariCell
CategoryWound Care Medical Devices (International)
Description

Fish-skin product line for International/EU markets for wound care applications, including MariCell Solid for wound care.

7MariGraft
CategoryWound Care Medical Devices (International)
Description

Fish-skin graft product for tissue regeneration in International/EU markets.

8MariSurgi
CategorySurgical Wound Care Devices (International)
Description

Fish-skin surgical product for operating room applications in International/EU markets.

9Kerecis Omega3 Wound
CategoryWound Care Medical Devices (International)
Description

Wound care product utilizing omega-3 rich fish skin technology for International/EU markets.

10Wunde
CategoryWound Care Medical Devices (International)
Description

Fish-skin wound dressing spray for wound care applications in international markets.

11Kerecis VET
CategoryVeterinary Medical Devices
Description

Fish-skin graft products specifically designed and available for veterinary/animal health applications, including Kerecis VET Solid for wound closure.

12Kerecis Current
CategoryDigital Healthcare Services
Description

Digital services platform aimed at improving patient care with faster digital services.

13MariCell SMOOTH
CategoryConsumer Personal Care Products
Description

Consumer product line derived from fish skin for personal care applications in international markets.

14MariCell FOOTGUARD
CategoryConsumer Personal Care Products
Description

Consumer foot care product derived from fish skin technology for international markets.

15MariCell XMA
CategoryConsumer Personal Care Products
Description

Consumer product derived from fish skin for skin care applications in international markets.

16MariCell PSORIA
CategoryConsumer Personal Care Products
Description

Consumer product for psoriasis care derived from fish skin technology for international markets.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
TypeDirect peer
Description

Organogenesis (ORG) markets Apligraf, Dermagraft, and PuraPly for chronic wound and surgical repair, directly overlapping Kerecis' chronic wound and burn care segments. Both compete for the same hospital outpatient reimbursement and wound clinic formularies.

TypeBroad incumbent
Description

Mölnlycke is a global wound care and surgical solutions leader (Mepilex, Avance NPWT) with established hospital relationships. It competes with Kerecis in the OR and outpatient wound segments, though Mölnlycke's portfolio does not include fish-skin grafts.

TypeDirect peer
Description

MiMedx is a direct competitor in the U.S. skin substitute market, selling placental-based grafts (EpiFix, AmnioFix) for chronic wounds including diabetic foot ulcers. Both companies compete for the same CMS-covered skin substitute reimbursement dollars and the same wound care specialist prescriber base.

TypeBroad incumbent
Description

Coloplast is Kerecis' parent company and one of the largest global wound care and ostomy players. Beyond the corporate relationship, Coloplast's broader wound care portfolio competes with other Kerecis alternatives in the same end markets and channels.

TypeDirect peer
Description

MTF Biologics provides a range of allograft skin substitutes (AmnioBand, AlloPatch) for chronic wound and surgical applications, competing directly with Kerecis in the same CMS-covered skin substitute category and wound care specialist market.

TypeEmerging player
Description

Cook Biotech develops and manufactures extracellular matrix grafts (Oasis, Biodesign) for wound care and surgical applications. It is a partial overlap with Kerecis in chronic wound and reconstructive surgery, though with a smaller wound care focus relative to Cook Medical's broader franchise.

TypeBroad incumbent
Description

Smith+Nephew is a large diversified wound care incumbent offering advanced wound dressings, NPWT, and skin substitutes. It competes with Kerecis across hospital and outpatient channels, though it is not focused specifically on fish-skin grafts.

TypeBroad incumbent
Description

ConvaTec is a major wound and ostomy care player with a broad advanced wound care portfolio (including InnovaMatrix placental graft) and competes with Kerecis in the same CMS skin substitute category and wound care specialist channel.

TypeBroad incumbent
Description

Integra LifeSciences markets regenerative tissue technologies (Integra Dermal Regeneration Template, AmnioExcel) for wound and reconstructive surgery, overlapping Kerecis' OR and burn segments. It is a much larger diversified medtech with broader portfolio reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds21 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kerecis

Wound Care Medical Deviceskerecis.com

Kerecis firmographics

Firmographics
Name
Kerecis
Legal name
Kerecis
Website
https://kerecis.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
251–500 employees
Ownership category
akta.pro rank

Kerecis industry classification

Industry
Product category
Wound Care Medical Devices
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAMANAG
Wound Healing & Dermatologic Regeneration
Healthcare & Life Sciences/Veterinary & Animal Health/Regenerative Medicine for Animals

Keywords

  • Fish skin grafts
  • Wound care medical devices
  • Tissue regeneration products
  • Skin substitute grafts
  • Burn care biologics

Where Kerecis is headquartered

Location

Headquarters

HQ city
Ísafjörður
HQ country
Iceland
HQ region
Europe

Offices5 records

Markets served

Kerecis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Device Sales: Kerecis generates revenue through the sale of fish-skin based medical devices for wound care, burn treatment, and surgical applications. Products are sold through healthcare providers, hospitals, and authorized distributors. The company operates as a subsidiary of Coloplast following acquisition.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCMS Reimbursement Rate - $127/cm²
Unit PricingPay-as-you-goMariGen Product Pricing

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Kerecis product offering

Product offering

Core offering

Kerecis develops and manufactures fish-skin based medical devices for wound healing, burn treatment, and surgical applications. The company uses intact fish skin from wild Atlantic cod sustainably sourced from Icelandic waters as a minimally processed, homologous-to-human-skin graft that supports true tissue regeneration. Its product portfolio includes the MariGen line for chronic wounds, Shield for wound care with silicone backing, SurgiClose and SurgiBind for surgical/operating room applications, and GraftGuide for burn management, supplemented by international product lines and a veterinary offering.

Product overview

Kerecis is a medical device company that has developed a proprietary fish-skin technology platform for tissue regeneration and wound healing. The company's products are based on intact fish skin sourced from wild Atlantic cod harvested from sustainable Icelandic fish stocks. The core portfolio includes MariGen (wound care - US), Shield (wound care with silicone backing), SurgiClose/SurgiClose Silicone (surgical applications), SurgiBind (operating room products), and GraftGuide (burn care). These products can be stacked or interspersed in deep wounds to fill deficits and support granulation tissue formation. The fish skin technology is homologous to human skin, provides structural support for cell ingrowth and vascularization, and maintains a natural bacterial barrier. Kerecis also offers veterinary products under the Kerecis VET brand and consumer products under the MariCell line for International/EU markets. The company provides digital services through Kerecis Current. All products are derived from sustainably sourced fish skin, processed using renewable energy with no harsh chemicals, and have a 3-year shelf life with room temperature storage.

Differentiator

Problem solved

Functional benefit

Brands

  • MariGen: Fish-skin graft product line for chronic wound management including diabetic foot ulcers, venous leg ulcers, and other hard-to-heal wounds. Available in multiple variations: Solid (intact fish skin), Fenestrated (pre-fenestrated for exudate drainage), Micro (fragmented for deep wound spaces), and Expanse (2:1 pre-meshed for large wounds).
  • MariCell
  • MariGraft
  • MariSurgi
  • SurgiClose
  • SurgiBind
  • Shield
  • GraftGuide
  • Kerecis VET
  • SMOOTH
  • FOOTGUARD
  • XMA
  • PSORIA
  • Wunde
  • Omega3 Wound

Products and services

  • MariGen Intact fish-skin graft product line for wound healing including diabetic foot ulcers, venous leg ulcers, and other chronic wounds. FDA-cleared with labeled intended use for full-thickness wounds with exposed bone and tendon. Available in Solid, Fenestrated, Micro, and Expanse variants.
  • Shield Fish-skin graft product with perforated silicone backing that protects the graft while managing exudate and wound moisture. Includes Shield Adhesive variant for outpatient wound care. Covered under CMS skin substitute program.
  • SurgiClose Intact fish-skin graft designed for operating room usage, including surgical and trauma wound care applications. SurgiClose Silicone combines intact fish skin with a non-adhesive silicone layer for exudate and moisture management; available in multiple sizes from 3x3 cm to 10x10 cm (bordered and borderless). SurgiClose Micro is fragmented for deep wound spaces.
  • SurgiBind Fish-skin graft product for operating room and surgical applications. SurgiBind Tendon Protect is designed to protect and manage newly repaired tendons to minimize scarring and adhesions. Available in fenestrated version for wound management.
  • GraftGuide Intact fish-skin graft used for burn wound management to support tissue regeneration and healing. Clinical evidence shows shorter hospital stays for severely burned patients treated with fish-skin grafts compared to synthetic products.
  • MariCell Fish-skin product line for International/EU markets for wound care applications, including MariCell Solid for wound care.
  • MariGraft Fish-skin graft product for tissue regeneration in International/EU markets.
  • MariSurgi Fish-skin surgical product for operating room applications in International/EU markets.
  • Kerecis Omega3 Wound Wound care product utilizing omega-3 rich fish skin technology for International/EU markets.
  • Wunde Fish-skin wound dressing spray for wound care applications in international markets.
  • Kerecis VET Fish-skin graft products specifically designed and available for veterinary/animal health applications, including Kerecis VET Solid for wound closure.
  • Kerecis Current Digital services platform aimed at improving patient care with faster digital services.
  • MariCell SMOOTH Consumer product line derived from fish skin for personal care applications in international markets.
  • MariCell FOOTGUARD Consumer foot care product derived from fish skin technology for international markets.
  • MariCell XMA Consumer product derived from fish skin for skin care applications in international markets.
  • MariCell PSORIA Consumer product for psoriasis care derived from fish skin technology for international markets.

Quantifiable outcome

  • 44% wound healing at 16 weeks vs 26.4% with standard of care for deep DFUs (Odinn RCT)
  • +7 more outcomes

Companies that use Kerecis

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Kerecis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Kerecis partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Kerecis competitors and assessment

Company assessment

Broad incumbents

  • 3M Health Care / Solventum:
  • Mölnlycke Health Care: Mölnlycke is a global wound care and surgical solutions leader (Mepilex, Avance NPWT) with established hospital relationships. It competes with Kerecis in the OR and outpatient wound segments, though Mölnlycke's portfolio does not include fish-skin grafts.
  • Coloplast: Coloplast is Kerecis' parent company and one of the largest global wound care and ostomy players. Beyond the corporate relationship, Coloplast's broader wound care portfolio competes with other Kerecis alternatives in the same end markets and channels.
  • Smith+Nephew: Smith+Nephew is a large diversified wound care incumbent offering advanced wound dressings, NPWT, and skin substitutes. It competes with Kerecis across hospital and outpatient channels, though it is not focused specifically on fish-skin grafts.
  • ConvaTec: ConvaTec is a major wound and ostomy care player with a broad advanced wound care portfolio (including InnovaMatrix placental graft) and competes with Kerecis in the same CMS skin substitute category and wound care specialist channel.
  • Integra LifeSciences: Integra LifeSciences markets regenerative tissue technologies (Integra Dermal Regeneration Template, AmnioExcel) for wound and reconstructive surgery, overlapping Kerecis' OR and burn segments. It is a much larger diversified medtech with broader portfolio reach.

Direct peers

  • Organogenesis: Organogenesis (ORG) markets Apligraf, Dermagraft, and PuraPly for chronic wound and surgical repair, directly overlapping Kerecis' chronic wound and burn care segments. Both compete for the same hospital outpatient reimbursement and wound clinic formularies.
  • MiMedx Group: MiMedx is a direct competitor in the U.S. skin substitute market, selling placental-based grafts (EpiFix, AmnioFix) for chronic wounds including diabetic foot ulcers. Both companies compete for the same CMS-covered skin substitute reimbursement dollars and the same wound care specialist prescriber base.
  • MTF Biologics: MTF Biologics provides a range of allograft skin substitutes (AmnioBand, AlloPatch) for chronic wound and surgical applications, competing directly with Kerecis in the same CMS-covered skin substitute category and wound care specialist market.

Emerging players

  • Cook Biotech (Cook Medical): Cook Biotech develops and manufactures extracellular matrix grafts (Oasis, Biodesign) for wound care and surgical applications. It is a partial overlap with Kerecis in chronic wound and reconstructive surgery, though with a smaller wound care focus relative to Cook Medical's broader franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Kerecis social profiles

Digital presence

Kerecis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kerecis leadership team

Management profile

Number of profiles

Profiles14 records

Kerecis funding detail

Funding detail

Funding overview

Funding rounds21 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kerecis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kerecis

What does Kerecis do?

Kerecis develops and manufactures fish-skin based medical devices for wound healing, burn treatment, and surgical applications. The company uses intact fish skin from wild Atlantic cod sustainably sourced from Icelandic waters as a minimally processed, homologous-to-human-skin graft that supports true tissue regeneration. Its product portfolio includes the MariGen line for chronic wounds, Shield for wound care with silicone backing, SurgiClose and SurgiBind for surgical/operating room applications, and GraftGuide for burn management, supplemented by international product lines and a veterinary offering.

Is Kerecis a public or private company?

Kerecis is a private company. It is classified as corporate owned and is currently operating.

When was Kerecis founded?

Kerecis was founded in 2013. It employs 251 to 500 people.

Where is Kerecis based?

Kerecis is headquartered in Ísafjörður, Iceland, in the Europe region.

How does Kerecis make money?

One revenue line is on record: medical Device Sales.

Who are Kerecis's main competitors?

Broad incumbents on record are 3M Health Care / Solventum, Mölnlycke Health Care, Coloplast, Smith+Nephew, ConvaTec and Integra LifeSciences. Direct peers are Organogenesis, MiMedx Group and MTF Biologics. Cook Biotech (Cook Medical) is listed as an emerging player.

Does Kerecis have an API?

No public API is recorded for Kerecis.

What industry is Kerecis in?

Kerecis's product category is Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireActive Wound Care Market worth $4.50 billion by 2031 - Exclusive Report by MarketsandMarkets™The active wound care market is projected to grow from $3.19 billion in 2026 to $4.50 billion by 2031, a 7.1% CAGR. North America held the largest regional share at 44.9% in 2025, and biological skin substitutes led product type with 56.8% share. Growth is driven by chronic wound prevalence and reimbursement changes, with M&A activity focusing on regenerative technologies.News-MedicalMore major insurance companies covering Kerecis intact fish-skin grafts as new studies show big benefits for burns and diabetic foot ulcersKerecis expanded U.S. insurance coverage for its intact fish-skin grafts, adding over 40 million covered lives across insurers and Medicaid programs. A study of 465 burn patients found hospital stays were 24.2 days versus 33.5 days for synthetic grafts, with lower graft loss. The company cites this evidence as driving payor confidence.New ScientistBurns improve more rapidly after treatment with fish skinA study indicates that severe burn patients treated with Kerecis's fish skin product, GraftGuide, spent 12 fewer days in hospital and experienced half the complication rate of those treated with synthetic substitutes. The research, funded by Kerecis but analyzed independently, suggests that omega-3 fatty acids in Atlantic cod skin facilitate faster healing through controlled inflammation. While these results are promising, experts note that formal head-to-head trials are still needed to confirm the findings.Mpo-magStudy Links Kerecis Intact Fish-Skin Grafts to Shorter Hospital StaysA retrospective study of 465 burn patients found intact fish-skin grafts reduced hospital stays by 9.3 days (24.2 vs 33.5 days). Graft loss was lower (3.2% vs 8.3%) and complication rates were numerically lower. The authors suggest fish-skin grafts may not require weeks of staged integration.FinancialContent Business PageKerecis Expands Insurance Coverage for Fish-Skin Grafts - 40 Million Covered Lives AddedKerecis announced a significant expansion of U.S. insurance coverage for its fish-skin grafts, adding more than 40 million covered lives through policy updates with multiple national and regional insurers as well as state Medicaid programs. The expansion positions Kerecis as one of the top-two widest covered skin substitutes for diabetic foot ulcers, supported by clinical data from the Odinn randomized controlled trial showing 44% wound healing at 16 weeks versus 26.4% with standard of care. The company, now part of Coloplast, expects the Medicare Advantage segment alignment to multiply patient access across both private and government-sponsored healthcare segments.Business Wire BlogKerecis Expands Insurance Coverage for Fish-Skin Grafts - 40 Million Covered Lives AddedKerecis expanded U.S. insurance coverage for its fish-skin grafts, adding over 40 million covered lives through policy updates with major insurers and state Medicaid programs. The company now ranks among the top two widest-covered skin substitutes for diabetic foot ulcers, with clinical data showing 44% healing at 16 weeks versus 26.4% with standard care.JournalStar.com8 Icelandic companies driving the future of life sciencesEight Icelandic life sciences companies are profiled, including Alvotech, deCODE Genetics, and Kerecis, which develop biosimilars, genetic insights, and wound treatments. The sector grew 23% over five years, with over 80% of companies clustered in Reykjavík. The companies aim to address global health challenges through innovation.Investing.comColoplast Q2 profit misses as Kerecis impairment and outlook weigh By Investing.comColoplast reported Q2 EBIT before special items of DKK 1.82 billion, missing the consensus median of DKK 1.89 billion, and set full-year EBIT growth guidance of around 5% in constant currencies, below the consensus median of 6%. The company also recognized a DKK 3 billion impairment on its Kerecis unit, citing Medicare reimbursement disruption.BioSpaceKerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 2026Kerecis will host two symposia and present multiple abstracts at EWMA-DEWU 2026 in Bremen, Germany, highlighting intact fish-skin grafts for wound care. The company notes the technology is well-established in the U.S. but early-stage adoption in Europe, with significant opportunity ahead.Business Wire BlogKerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 2026Kerecis will present intact fish-skin grafts at EWMA-DEWU 2026 in Bremen, hosting two symposia and five accepted abstracts. The company highlights growing clinical experience and early-stage adoption in Europe, citing significant opportunity ahead.